The PI3K-AKT signaling pathway is activated in over 60% of ER+ breast cancer and contributes to resistance to ER inhibition and progression [40,41] and MCF7 cells carry mutations typically found in human luminal breast cancers, including PIK3CA E545K [42,43]. This evidence concerns the gene ESR1 and breast carcinoma.